AtriCure (NASDAQ:ATRC) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS

AtriCure (NASDAQ:ATRC) posted its earnings results on Tuesday. The medical device company reported $0.00 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.07, reports. AtriCure had a positive return on equity of 0.29% and a negative net margin of 0.83%.The business had revenue of $141.25 million during the quarter, compared to analysts’ expectations of $139.75 million. During the same period in the previous year, the business earned ($0.14) earnings per share. The firm’s revenue was up 14.3% on a year-over-year basis. AtriCure updated its FY 2026 guidance to 0.000-0.040 EPS.

Here are the key takeaways from AtriCure’s conference call:

• Q1 worldwide revenue of $141.2 million (up ~14% YoY) drove a near-doubling of adjusted EBITDA to $17.1 million and a breakeven net income, with gross margin improving to 77.4% (+246 bps).
• The BoxX-NoAF randomized trial is enrolling ~300 of 960 patients and is tracking ~1 year ahead of plan, with full enrollment expected around the end of 2026 — a catalytic data event that could materially expand the addressable market for postoperative AFib prevention.
• Product momentum is driving growth — pain management (cryoSPHERE MAX) grew ~28% and contributed ~70% of pain sales, while open ablation (EnCompass Clamp) and appendage management (AtriClip FLEX?Mini, which represented ~40% of U.S. open appendage revenue) continue to gain adoption.
• Management reiterated full?year guidance of $600–$610 million revenue and $80–$82 million adjusted EBITDA, but accelerated BoxX-NoAF enrollment will raise R&D spending over the next three quarters (company expects to absorb the incremental cost).
• Headwinds remain in minimally invasive (MIS) ablation — U.S. MIS sales fell ~25% YoY — and international growth is uneven (11.5% reported, 3.3% constant currency) due to U.K. uncertainty and lumpy APAC distributor orders.

AtriCure Trading Down 0.7%

Shares of NASDAQ ATRC traded down $0.21 during midday trading on Thursday, reaching $27.80. The company had a trading volume of 1,005,702 shares, compared to its average volume of 712,631. AtriCure has a one year low of $26.62 and a one year high of $43.18. The company has a quick ratio of 2.99, a current ratio of 3.96 and a debt-to-equity ratio of 0.13. The firm’s fifty day moving average price is $29.24 and its 200-day moving average price is $34.28. The stock has a market cap of $1.41 billion, a PE ratio of -278.00 and a beta of 1.28.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ATRC shares. Canaccord Genuity Group lifted their price target on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday. Freedom Capital raised AtriCure to a “strong-buy” rating in a research note on Wednesday, April 1st. JPMorgan Chase & Co. lowered AtriCure from an “overweight” rating to a “neutral” rating and set a $36.00 price target for the company. in a research note on Wednesday, February 11th. Citigroup reaffirmed an “outperform” rating on shares of AtriCure in a research note on Wednesday, February 18th. Finally, Weiss Ratings lowered AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, AtriCure presently has a consensus rating of “Moderate Buy” and an average price target of $48.71.

Insider Buying and Selling at AtriCure

In other news, insider Vinayak Doraiswamy sold 5,000 shares of the business’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $29.83, for a total value of $149,150.00. Following the completion of the sale, the insider owned 96,875 shares of the company’s stock, valued at approximately $2,889,781.25. The trade was a 4.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On AtriCure

A number of hedge funds and other institutional investors have recently modified their holdings of ATRC. Smartleaf Asset Management LLC increased its holdings in AtriCure by 59.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares during the period. Scotia Capital Inc. increased its holdings in AtriCure by 1.2% during the 3rd quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock valued at $1,328,000 after purchasing an additional 457 shares during the period. Captrust Financial Advisors increased its holdings in AtriCure by 7.9% during the 4th quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock valued at $314,000 after purchasing an additional 579 shares during the period. Mackenzie Financial Corp increased its holdings in AtriCure by 5.3% during the 4th quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock valued at $545,000 after purchasing an additional 683 shares during the period. Finally, California State Teachers Retirement System increased its holdings in AtriCure by 1.6% during the 2nd quarter. California State Teachers Retirement System now owns 45,001 shares of the medical device company’s stock valued at $1,475,000 after purchasing an additional 691 shares during the period. Institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.